Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers.

Nature communications·2025
Same author

The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma.

Nature communications·2025
Same author

Chromobox 4 (CBX4) Is a Novel Interactor of SS18::SSX in Synovial Sarcoma.

Laboratory investigation; a journal of technical methods and pathology·2025
Same author

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatment.

Oncogene·2025
Same author

DNA demethylating agents suppress preclinical models of synovial sarcoma.

The Journal of clinical investigation·2025
Same author

Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.

NPJ breast cancer·2025

Related Experiment Video

Updated: Nov 8, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.2K

Synovial Sarcoma Oncogenesis Revealed by Single-Cell Profiling.

Alvin Qiu1, Torsten O Nielsen1

  • 1Faculty of Medicine, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.

Trends in Cancer
|April 24, 2021
PubMed
Summary
This summary is machine-generated.

Researchers identified a core oncogenic program in synovial sarcoma, driven by the SS18-SSX oncoprotein. This discovery offers new therapeutic targets for this soft tissue cancer, focusing on epigenetics, cell cycle, and immune response.

Keywords:
SS18–SSXepigeneticsimmune exclusionsingle-cellsynovial sarcoma

More Related Videos

Author Spotlight: Shear Assay Protocol for the Determination of Single-Cell Material Properties
08:19

Author Spotlight: Shear Assay Protocol for the Determination of Single-Cell Material Properties

Published on: May 19, 2023

2.2K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.1K

Related Experiment Videos

Last Updated: Nov 8, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.2K
Author Spotlight: Shear Assay Protocol for the Determination of Single-Cell Material Properties
08:19

Author Spotlight: Shear Assay Protocol for the Determination of Single-Cell Material Properties

Published on: May 19, 2023

2.2K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.1K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Synovial sarcoma is a rare soft tissue malignancy.
  • The SS18-SSX fusion oncoprotein is the primary driver of synovial sarcoma development.
  • Understanding the molecular mechanisms driving synovial sarcoma is crucial for developing effective treatments.

Purpose of the Study:

  • To characterize the molecular landscape of synovial sarcoma at a single-cell level.
  • To identify the core oncogenic program driven by the SS18-SSX fusion oncoprotein.
  • To explore potential therapeutic strategies based on the identified molecular drivers.

Main Methods:

  • Generation and analysis of a single-cell RNA sequencing dataset from synovial sarcoma tumors.
  • Bioinformatic analysis to identify gene expression patterns and regulatory networks.
  • Integration of single-cell data with existing knowledge of cancer biology.

Main Results:

  • Discovery of a novel 'core oncogenic program' regulated by SS18-SSX.
  • Identification of key pathways involved in synovial sarcoma pathogenesis, including epigenetic regulation and cell-cycle control.
  • Characterization of the tumor microenvironment and immune cell populations within synovial sarcoma.

Conclusions:

  • The SS18-SSX oncoprotein orchestrates a core oncogenic program in synovial sarcoma.
  • Targeting epigenetic modifiers, cell-cycle regulators, or immune checkpoints may represent effective treatment strategies.
  • Single-cell analysis provides unprecedented insights into the heterogeneity and complexity of synovial sarcoma.